Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thirty-eight patients who had undergone reoperations because of complications or implant failure subsequent to a prosthetic replacement for limb salvage procedure for the treatment of musculoskeletal neoplasm were followed until death or a minimum of 2 years, then reviewed. The mean follow-up time before reoperation was 35 months, and the mean follow-up time after reoperation was 51 months. The major indication for reoperation was aseptic loosening (34%). The reoperative procedures included 19 major revisions of the prosthesis and 19 other reconstructions. There were 7 complications, including 1 local tumor recurrence. Twelve patients died of metastatic disease at a mean of 16 months after reoperation. The probability for patient survival was 74% beyond 3 years and 67% after 5 years. The surgical staging, site of tumor involvement, and type of reoperation all correlated with long-term patient survival. Overall, 72% of the patients achieved excellent or good functional results: a rate that was slightly inferior to that of the initial arthroplasty. Despite this, 84% of the implants demonstrated either excellent or good performance at 5 years. Therefore, reoperation because of a failed initial prosthesis or for other reasons after a limb salvage procedure using custom-designed or modular-segmental bone and joint implants seems feasible with no significant effect on subsequent functional performance or on patient survival.
 ...
PMID:Reoperation results after segmental prosthetic replacement of bone and joint for limb salvage. 1047 48

Recent advances in PET technology and applications have led to a proliferation in PET and PET/CT imaging, allowing correlation of both physiologic and anatomic information. This has also led to new and innovative ways to utilize PET imaging for the evaluation of musculoskeletal neoplasm. Currently, the most widely utilized musculoskeletal application of F-18 FDG-PET imaging is for the detection and characterization of osseous metastatic disease. The other notable potential role for FDG-PET imaging is for staging and restaging of primary bone tumors and soft tissue sarcomas. Precise staging and restaging of musculoskeletal neoplasm is critical to optimize treatment planning and to accurately determine patient prognosis. FDG-PET is also useful in evaluating response to therapy for musculoskeletal tumors. The future likely holds even more unique and potentially quite useful applications of PET imaging for primary osseous and soft tumors. This article will review the common and potentially useful applications of F-18 FDG-PET imaging for evaluating musculoskeletal tumors and malignancy.
 ...
PMID:F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors. 1826 35